Helperby Therapeutics

What Helperby Therapeutics does

Helperby Therapeutics is a clinical-stage biopharmaceutical company founded as a spinout from St George's Hospital, University of London, that develops synergistic combinations of already-approved antimicrobials to treat bacterial infections caused by WHO Critical and High Priority pathogens. The company's core technology combines two or more approved anti-infectives of different types into synergistic formulations that, per management, are 100s to 1,000s fold more effective than single antibiotics alone and can be deployed at substantially lower doses; for example, the company cites colistin use at less than one-third of the recommended dose with significantly higher bacterial kill, including against colistin-resistant strains. Lead product HY001 has confirmed activity in Phase I human studies, and the pipeline has been expanded to include combinations targeting complicated urinary tract infections (cUTI), acute bacterial skin and soft tissue infections (ASSSI), hospital-acquired/ventilator-associated pneumonia (HA/VABP), bloodstream infections, and a planned oral program for community-acquired infections.

The company operates a fully virtual model, with headquarters in London and additional offices in Dublin and Bedford, New Hampshire, to support US and EU regulatory activity. Its revenue model is licensing-driven: Helperby licenses its technology and combination know-how to pharma companies holding approved, still patent-protected antibiotics, and seeks manufacturing and commercialisation partners in the US, Canada, Europe, the Middle East, Japan, China and India. Regulatory submissions are pursued via the US FDA 505b2 pathway and equivalent EU filing routes, which management cites as enabling regulatory approval in Year 3 versus Year 11 for new chemical entities, with a 6.7x higher probability of clinical success and profitability achievable in Year 4 versus Year 23. The company has not disclosed executed licensing transactions, product revenues, or headcount, and is currently in an open fundraising round while seeking global commercialisation partners.

Name

Helperby Therapeutics

Legal name

Helperby Therapeutics

Website

https://helperby.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Helperby Therapeutics is a clinical-stage, UK-based biopharmaceutical company developing synergistic combinations of already-approved antibiotics to treat WHO Critical and High Priority bacterial infections, targeting hospital-acquired infections via US 505b2 and EU filing routes.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Technology: Licensing Helperby technology to pharma companies who have approved antibiotics which remain patent-protected and would benefit from increased activity vs AMR and lower doses giving lower adverse events from increased activity. Helperby can undertake work on behalf of, jointly with or support partners who prefer internal working of all or part of programs.
2. Manufacturing and Commercialisation Licensing: Licensing rights to manufacture and commercialise antibiotic combinations to biopharma and pharma companies for US, Canada, Europe, Middle East, Japan, China, India and other key geographies.
3. Product Sales: Revenue from sale of antibiotic combination products targeting complicated urinary tract (cUTI) and skin and soft tissue structure (ASSSI) infections. Global Ph III study supporting US NDA by 505b2 and EU filing routes.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Helperby Therapeutics is a clinical-stage biopharmaceutical company that develops synergistic combinations of already-approved anti-infective drugs to treat WHO Critical and High Priority bacterial infections resistant to existing antibiotics. The company licenses its proprietary combination technology and IP to pharmaceutical and biopharmaceutical partners for manufacturing, distribution, and commercialisation across global markets, while pursuing a 505b2 regulatory pathway in the US and equivalent EU filing routes.

Product overview

Helperby Therapeutics is a clinical-stage biopharmaceutical company developing synergistic combinations of already-approved antimicrobials to treat WHO Critical and High Priority bacterial infections. The company's portfolio includes its lead product HY001 (confirmed in Phase I studies), along with combinations targeting complicated urinary tract infections (cUTI), acute bacterial skin and soft tissue structure infections (ASSSI), hospital-acquired/ventilator-associated pneumonia (HA/VABP), and bloodstream infections (BSI). All products use a 505b2 regulatory pathway leveraging approved drugs, with the company's proprietary synergistic combination approach providing 100s to 1,000s fold greater efficacy than single antibiotics alone. The company also plans to expand into oral antibiotic combinations for community infections.

Differentiator

Problem solved

Functional benefit

Products and services

• HY001

Quantifiable outcome

• 100s to 1,000s fold more effective than single antibiotics alone
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• GARDP (Global Antibiotic Research and Development Partnership)coreStrategic or Co-development Partner · 22 July 2025Helperby's founder Prof Sir Anthony Coates participated as a keynote speaker at GARDP's REVIVE campaign webinar titled 'Repurposing Drugs to address the crisis of antimicrobial resistance'. GARDP is a global partnership working to develop new antibiotic treatments and ensure access to existing ones.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Iterum Therapeutics: Clinical-stage company developing oral and IV antibiotics against resistant pathogens, including complicated urinary tract infections. Highly comparable to Helperby's cUTI program and AMR-focused, small-cap antibiotics development model.
• Nabriva Therapeutics: Biopharmaceutical company developing antibiotics for serious infections, including community-acquired pneumonia. Comparable to Helperby as a small-cap antibiotics developer with hospital-targeted products and partnership-oriented commercialization.
• Spero Therapeutics: Clinical-stage biopharmaceutical company developing novel antibiotics for multidrug-resistant infections, including agents targeting WHO priority pathogens. Directly comparable to Helperby as a small, capital-efficient antibiotics developer focused on AMR and pursuing licensing/commercialization partnerships.
• Entasis Therapeutics (an Innoviva company): Clinical-stage antibiotics developer targeting serious multidrug-resistant infections, including WHO priority pathogens. Comparable to Helperby in therapeutic focus on AMR and in reliance on partner-driven commercialization of hospital antibiotics.
• VenatoRx Pharmaceuticals: Privately-held clinical-stage antibiotics company developing therapies for drug-resistant bacterial infections, including β-lactamase inhibitor combinations. Closely comparable to Helperby in AMR focus, combination approach, and late-stage clinical development profile.
• Allecra Therapeutics: Clinical-stage company developing novel antibiotics to combat drug-resistant bacteria, with programs targeting WHO priority pathogens. Directly comparable to Helperby in mission, stage, and AMR-focused combination/synergy strategy.
• Paratek Pharmaceuticals: Specialty biopharmaceutical company developing antibiotics for serious community- and hospital-based infections, including resistant pathogens. Comparable to Helperby in therapeutic area, hospital-channel focus, and reliance on partnership-driven commercialization.
• Melinta Therapeutics: Commercial-stage antibiotics company with a portfolio covering serious and life-threatening infections, including agents used in hospital settings. Comparable to Helperby in therapeutic focus on resistant bacterial infections and pursuit of hospital-channel partners.

Broad incumbents

• Pfizer: Large pharmaceutical company with a broad antibiotics portfolio and significant AMR R&D investment. Relevant as a likely partner/licensor for Helperby's combination assets given its global hospital-antibiotic commercialization infrastructure.
• GSK: Global pharmaceutical company with a long-standing antibiotics franchise and public commitments to AMR stewardship. Comparable as a large incumbent that could partner with or compete against Helperby's combination approach to resistant infections.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/helperby-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helperby Therapeutics